The chronic pain market is expected to grow significantly, reaching US$ 78,186.20 million in 2024. This growth is driven by the increasing prevalence of chronic diseases, the aging population, the need for over-the-counter pain medications, awareness of alternative therapies, and a focus on research and development. Following these dynamics, the market is expected to reach US$ 152,372.7 million by 2034, exhibiting a CAGR of 6.90%.
Chronic Pain Market Dynamics
| Attributes | Details |
|---|---|
| Market Value for 2024 | US$ 78,186.20 million |
| Projected Market Value for 2034 | US$ 152,372.7 million |
| Value-based CAGR of Market for 2024 to 2034 | 6.90% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The drug segment is gaining significant market share in chronic pain, particularly neuropathic pain, which requires a delicate balance for effective treatment.
The drug segment is projected to dominate pain management, with a market share of 68.90% in 2024.
| Attributes | Details |
|---|---|
| Top Product | Drugs |
| Market Share (2024) | 68.9% |
The neuropathic pain segment is projected to experience significant growth, accounting for 28.4% of the market share in 2024. This is driven by the growing demand for pain management solutions for various neuropathic conditions.
| Attributes | Details |
|---|---|
| Indication | Neuropathic Pain |
| Market Share (2024) | 28.4% |
North America holds the major market share, with the aging population and high healthcare expenditure, especially in the United States and Canada. This is contributing significantly to the prevalence of chronic health conditions. This results in a robust demand for pain management treatments.
In Europe, countries like Germany, the United Kingdom, and Russia contribute significantly. Regulatory bodies support market growth by approving drugs for chronic pain treatments. There are well-established healthcare systems that ensure accessibility to pain management therapies.
Asia Pacific is expected to be the fastest-growing region. Developments are driven by growing awareness and infrastructure, with urbanization and economic growth also driving the demand for healthcare services, including pain management.
| Countries | CAGR (2024 to 2034) |
|---|---|
| Russia | 7.00% |
| United Kingdom | 8.40% |
| Canada | 10.80% |
| Japan | 7.80% |
| Spain | 6.30% |
The chronic pain market in Russia is expected to grow at a CAGR of 7.00% due to various factors, such as:
The growing number of chronic diseases, such as arthritis, cancer, and diabetes, has led to an augmented demand for pain administration therapies, thereby driving the growth of the market in Russia.
The chronic pain market in the United Kingdom is experiencing growth at a CAGR of 8.40%, driven by factors such as:
The advancement in health technologies and an increasing acceptance of pain management therapies have led to an increased demand for pain management drugs and devices, leading to market growth.
Canada’s chronic pain market is expanding at a CAGR of 10.80%. This growth can be attributed to the availability of advanced and innovative treatment options. The accessibility of advanced and innovative treatment options, such as non-opioid pain medications and minimally invasive procedures, is also contributing to market growth.
Japan’s chronic pain market is expanding with a CAGR of 7.80% due to various factors. One of the main reasons is the aging population in the country, with a large number of elderly people suffering from prolonged pain. Non-opioid pain medication and minimally invasive procedures are contributing to the growth of the market. The rising awareness about the benefits of early diagnosis and treatment of acute pain is encouraging more patients to seek medical help, driving the market growth.
In Spain, the market is expanding with a CAGR of 6.30% due to the rising demand for effective pain management treatments. The population in Spain is more likely to experience chronic pain, which is driving market progression. Additionally, increased awareness among patients about the need for effective pain management is also boosting the market growth in Spain.
Principal Consultant
The market provides a range of products and options for chronic pain management, such as opioids, non-opioid analgesics, and nerve-block therapies. Companies are searching for the emergence of new players like startups to work on developing innovative therapies for pain management. This is a highly competitive market where industries are prioritizing patient safety, efficacy, and affordability, expected to thrive.
Recent Developments
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The size of the market is estimated to be US$ 78,186.20 million in 2024.
The market is expected to increase at a CAGR of 6.90% over the forecast period.
The market is expected to register a CAGR of 10.80% in Canada from 2024 to 2034.
The market is forecasted to reach a size of US$ 152,372.7 million by 2034.
Eli Lilly and Company, Dickinson and Company, Medtronic plc, Johnson & Johnson, Novartis AG, AstraZeneca PLC, Becton, Bristol-Myers Squibb Company, Sanofi.
Drugs are the top product type in the market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2024 to 2034 5.3.1. Drugs 5.3.2. Devices 5.4. Y-o-Y Growth Trend Analysis By Product, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Product, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2024 to 2034 6.3.1. Neuropathic Pain 6.3.2. Arthritis Pain 6.3.3. Chronic Back Pain 6.3.4. Cancer Pain 6.3.5. Migraine 6.3.6. Fibromyalgia 6.3.7. Others 6.4. Y-o-Y Growth Trend Analysis By Indication, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Indication, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2024 to 2034 7.3.1. Musculoskeletal 7.3.2. Neuropathy 7.3.3. Oncology 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019 to 2023 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024 to 2034 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034 9.3.1. North America 9.3.2. Latin America 9.3.3. Western Europe 9.3.4. Eastern Europe 9.3.5. South Asia and Pacific 9.3.6. East Asia 9.3.7. Middle East and Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Product 10.2.3. By Indication 10.2.4. By Application 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product 10.3.3. By Indication 10.3.4. By Application 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Product 11.2.3. By Indication 11.2.4. By Application 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product 11.3.3. By Indication 11.3.4. By Application 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. UK 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Western Europe 12.2.2. By Product 12.2.3. By Indication 12.2.4. By Application 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product 12.3.3. By Indication 12.3.4. By Application 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. Poland 13.2.1.2. Russia 13.2.1.3. Czech Republic 13.2.1.4. Romania 13.2.1.5. Rest of Eastern Europe 13.2.2. By Product 13.2.3. By Indication 13.2.4. By Application 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product 13.3.3. By Indication 13.3.4. By Application 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Bangladesh 14.2.1.3. Australia 14.2.1.4. New Zealand 14.2.1.5. Rest of South Asia and Pacific 14.2.2. By Product 14.2.3. By Indication 14.2.4. By Application 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product 14.3.3. By Indication 14.3.4. By Application 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Product 15.2.3. By Indication 15.2.4. By Application 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Product 15.3.3. By Indication 15.3.4. By Application 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Product 16.2.3. By Indication 16.2.4. By Application 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Product 16.3.3. By Indication 16.3.4. By Application 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2023 17.1.2.1. By Product 17.1.2.2. By Indication 17.1.2.3. By Application 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2023 17.2.2.1. By Product 17.2.2.2. By Indication 17.2.2.3. By Application 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2023 17.3.2.1. By Product 17.3.2.2. By Indication 17.3.2.3. By Application 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2023 17.4.2.1. By Product 17.4.2.2. By Indication 17.4.2.3. By Application 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2023 17.5.2.1. By Product 17.5.2.2. By Indication 17.5.2.3. By Application 17.5.2.4. By Distribution Channel 17.6. UK 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2023 17.6.2.1. By Product 17.6.2.2. By Indication 17.6.2.3. By Application 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2023 17.7.2.1. By Product 17.7.2.2. By Indication 17.7.2.3. By Application 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2023 17.8.2.1. By Product 17.8.2.2. By Indication 17.8.2.3. By Application 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2023 17.9.2.1. By Product 17.9.2.2. By Indication 17.9.2.3. By Application 17.9.2.4. By Distribution Channel 17.10. Poland 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2023 17.10.2.1. By Product 17.10.2.2. By Indication 17.10.2.3. By Application 17.10.2.4. By Distribution Channel 17.11. Russia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2023 17.11.2.1. By Product 17.11.2.2. By Indication 17.11.2.3. By Application 17.11.2.4. By Distribution Channel 17.12. Czech Republic 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2023 17.12.2.1. By Product 17.12.2.2. By Indication 17.12.2.3. By Application 17.12.2.4. By Distribution Channel 17.13. Romania 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2023 17.13.2.1. By Product 17.13.2.2. By Indication 17.13.2.3. By Application 17.13.2.4. By Distribution Channel 17.14. India 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2023 17.14.2.1. By Product 17.14.2.2. By Indication 17.14.2.3. By Application 17.14.2.4. By Distribution Channel 17.15. Bangladesh 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2023 17.15.2.1. By Product 17.15.2.2. By Indication 17.15.2.3. By Application 17.15.2.4. By Distribution Channel 17.16. Australia 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2023 17.16.2.1. By Product 17.16.2.2. By Indication 17.16.2.3. By Application 17.16.2.4. By Distribution Channel 17.17. New Zealand 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2023 17.17.2.1. By Product 17.17.2.2. By Indication 17.17.2.3. By Application 17.17.2.4. By Distribution Channel 17.18. China 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2023 17.18.2.1. By Product 17.18.2.2. By Indication 17.18.2.3. By Application 17.18.2.4. By Distribution Channel 17.19. Japan 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2023 17.19.2.1. By Product 17.19.2.2. By Indication 17.19.2.3. By Application 17.19.2.4. By Distribution Channel 17.20. South Korea 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2023 17.20.2.1. By Product 17.20.2.2. By Indication 17.20.2.3. By Application 17.20.2.4. By Distribution Channel 17.21. GCC Countries 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2023 17.21.2.1. By Product 17.21.2.2. By Indication 17.21.2.3. By Application 17.21.2.4. By Distribution Channel 17.22. South Africa 17.22.1. Pricing Analysis 17.22.2. Market Share Analysis, 2023 17.22.2.1. By Product 17.22.2.2. By Indication 17.22.2.3. By Application 17.22.2.4. By Distribution Channel 17.23. Israel 17.23.1. Pricing Analysis 17.23.2. Market Share Analysis, 2023 17.23.2.1. By Product 17.23.2.2. By Indication 17.23.2.3. By Application 17.23.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Product 18.3.3. By Indication 18.3.4. By Application 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Eli Lilly and Company 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Dickinson and Company 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Medtronic plc 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Johnson & Johnson 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Novartis AG 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. AstraZeneca PLC 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Becton 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Bristol-Myers Squibb Company 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Sanofi 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Chronic Pain Market
